Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stuart Tafeen

Dermatology Greensboro, NC Medical Doctor

NPI 1508827098 CMS profile 204479

1900 Ashwood Ct, Greensboro, NC 27455

Open in the dashboard

General payments

$3,963

236 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stuart Tafeen of Greensboro, NC is reported in the CMS Open Payments database as having received $3,963 across 236 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 59th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $694 31
2023 General $877 38
2022 General $439 29
2021 General $272 23
2020 General $348 20
2019 General $1,333 95

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stuart Tafeen
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Stuart Tafeen were reported at $694. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Stuart Tafeen Dermatology median Middle half National median
2019 $1,333 $454 $129–$1,240 $163
2020 $348 $235 $81–$756 $114
2021 $272 $377 $108–$1,108 $132
2022 $439 $514 $143–$1,391 $149
2023 $877 $607 $159–$1,674 $160
2024 $0 $751 $204–$1,903 $164
2025 $694 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,239 81 payments
  2. Novartis Pharmaceuticals Corporation $421 29 payments
  3. Regeneron Healthcare Solutions, Inc. $290 12 payments
  4. LEO Pharma Inc. $262 15 payments
  5. Sun Pharmaceutical Industries Inc. $250 11 payments
  6. Genzyme Corporation $189 9 payments
  7. Amgen Inc. $148 6 payments
  8. Celgene Corporation $143 21 payments
  9. Organogenesis Inc. $130 4 payments
  10. UCB, Inc. $127 6 payments
  11. Other $764 42 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,883 235 payments
  2. Education $80 1 payment
Products named General payments · program years 2019–2025
  1. SKYRIZI Immunology $718 51 payments
  2. HUMIRA $383 24 payments
  3. RINVOQ $241 14 payments
  4. DUPIXENT Inflammation And Immunology $224 9 payments
  5. COSENTYX $191 18 payments
  6. DUPIXENT Immunology $174 8 payments
  7. ADBRY $168 9 payments
  8. Otezla $143 21 payments
  9. SKYRIZI Immunology $141 8 payments
  10. ILUMYA $134 8 payments
  11. Other $2,032 102 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

236 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record